Crispr Therapeutics AG (NASDAQ:CRSP) was the target of a significant decrease in short interest in December. As of December 13th, there was short interest totalling 3,400,000 shares, a decrease of 6.1% from the November 28th total of 3,620,000 shares. Based on an average trading volume of 1,000,000 shares, the days-to-cover ratio is currently 3.4 days. Currently, 9.9% of the shares of the stock are short sold.
NASDAQ:CRSP traded down $0.88 on Tuesday, hitting $60.96. 66,332 shares of the stock were exchanged, compared to its average volume of 985,084. The stock has a market cap of $3.64 billion, a PE ratio of -17.72 and a beta of 3.30. The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 0.06. The stock has a fifty day moving average of $65.47 and a 200-day moving average of $50.80. Crispr Therapeutics has a fifty-two week low of $27.11 and a fifty-two week high of $74.00.
Crispr Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Monday, October 28th. The company reported $2.40 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.95) by $3.35. The company had revenue of $211.93 million during the quarter, compared to analyst estimates of $6.32 million. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. As a group, analysts predict that Crispr Therapeutics will post 0.65 earnings per share for the current year.
Several equities analysts recently weighed in on the company. Oppenheimer increased their target price on Crispr Therapeutics from $65.00 to $80.00 and gave the stock an “outperform” rating in a research report on Monday, November 25th. William Blair upgraded Crispr Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, November 19th. Zacks Investment Research downgraded Crispr Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 30th. Needham & Company LLC reiterated a “buy” rating and set a $84.00 target price on shares of Crispr Therapeutics in a research report on Monday, December 23rd. Finally, BidaskClub downgraded Crispr Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, December 13th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and fourteen have assigned a buy rating to the company’s stock. Crispr Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $71.38.
In related news, President Rodger Novak sold 33,618 shares of the stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the transaction, the president now directly owns 33,618 shares in the company, valued at $2,353,260. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Pablo J. Cagnoni sold 7,500 shares of the stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $55.00, for a total value of $412,500.00. Following the transaction, the director now owns 7,500 shares in the company, valued at $412,500. The disclosure for this sale can be found here. Insiders sold 56,118 shares of company stock worth $3,620,760 over the last 90 days. Company insiders own 21.40% of the company’s stock.
Large investors have recently made changes to their positions in the business. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Crispr Therapeutics by 13.6% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,870 shares of the company’s stock valued at $118,000 after buying an additional 343 shares in the last quarter. Traynor Capital Management Inc. grew its stake in shares of Crispr Therapeutics by 5.8% in the third quarter. Traynor Capital Management Inc. now owns 6,845 shares of the company’s stock valued at $280,000 after buying an additional 375 shares in the last quarter. Commonwealth Equity Services LLC grew its stake in shares of Crispr Therapeutics by 2.2% in the third quarter. Commonwealth Equity Services LLC now owns 18,201 shares of the company’s stock valued at $746,000 after buying an additional 386 shares in the last quarter. D. E. Shaw & Co. Inc. grew its stake in shares of Crispr Therapeutics by 7.1% in the second quarter. D. E. Shaw & Co. Inc. now owns 7,019 shares of the company’s stock valued at $331,000 after buying an additional 467 shares in the last quarter. Finally, US Bancorp DE grew its stake in shares of Crispr Therapeutics by 553.7% in the second quarter. US Bancorp DE now owns 621 shares of the company’s stock valued at $29,000 after buying an additional 526 shares in the last quarter. Institutional investors own 49.82% of the company’s stock.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Further Reading: Why Invest in Dividend Achievers?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.